American Century Companies Inc. Buys 12,682 Shares of Health Catalyst, Inc. (NASDAQ:HCAT)

American Century Companies Inc. raised its stake in shares of Health Catalyst, Inc. (NASDAQ:HCAT) by 1.8% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 710,481 shares of the company’s stock after purchasing an additional 12,682 shares during the period. American Century Companies Inc. owned 1.17% of Health Catalyst worth $5,023,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently made changes to their positions in the company. Legato Capital Management LLC boosted its stake in Health Catalyst by 3.7% during the fourth quarter. Legato Capital Management LLC now owns 87,992 shares of the company’s stock valued at $622,000 after buying an additional 3,171 shares during the last quarter. Quantbot Technologies LP bought a new position in shares of Health Catalyst during the 4th quarter valued at approximately $29,000. SG Americas Securities LLC increased its position in Health Catalyst by 21.7% in the fourth quarter. SG Americas Securities LLC now owns 27,382 shares of the company’s stock worth $194,000 after purchasing an additional 4,874 shares during the last quarter. Franklin Resources Inc. increased its position in Health Catalyst by 5.8% in the third quarter. Franklin Resources Inc. now owns 104,141 shares of the company’s stock worth $857,000 after purchasing an additional 5,687 shares during the last quarter. Finally, Inspire Investing LLC raised its stake in Health Catalyst by 14.2% during the fourth quarter. Inspire Investing LLC now owns 56,379 shares of the company’s stock valued at $399,000 after purchasing an additional 7,019 shares in the last quarter. Hedge funds and other institutional investors own 85.00% of the company’s stock.

Insiders Place Their Bets

In other Health Catalyst news, COO Daniel Lesueur sold 16,902 shares of the stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $4.52, for a total transaction of $76,397.04. Following the completion of the sale, the chief operating officer now directly owns 216,250 shares of the company’s stock, valued at approximately $977,450. This represents a 7.25 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Linda Llewelyn sold 6,442 shares of the firm’s stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $5.80, for a total transaction of $37,363.60. Following the completion of the sale, the insider now owns 92,260 shares in the company, valued at $535,108. This represents a 6.53 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 56,530 shares of company stock worth $299,572 in the last ninety days. 2.50% of the stock is owned by company insiders.

Health Catalyst Stock Performance

Shares of NASDAQ:HCAT opened at $4.01 on Friday. The firm’s 50 day simple moving average is $4.89 and its 200-day simple moving average is $6.73. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.41 and a current ratio of 1.41. Health Catalyst, Inc. has a one year low of $3.72 and a one year high of $9.24. The firm has a market cap of $281.55 million, a PE ratio of -2.97 and a beta of 1.43.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the stock. Stifel Nicolaus reduced their target price on shares of Health Catalyst from $10.00 to $5.00 and set a “hold” rating on the stock in a report on Thursday, February 27th. Stephens cut their target price on Health Catalyst from $7.00 to $5.00 and set an “equal weight” rating on the stock in a research report on Thursday, March 6th. Piper Sandler lowered their price target on Health Catalyst from $12.00 to $8.00 and set an “overweight” rating for the company in a research report on Tuesday, February 11th. Canaccord Genuity Group reduced their target price on shares of Health Catalyst from $11.00 to $10.00 and set a “buy” rating on the stock in a research note on Tuesday, January 21st. Finally, KeyCorp upgraded shares of Health Catalyst from a “sector weight” rating to an “overweight” rating and set a $9.00 target price for the company in a report on Wednesday, January 8th. Three research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $9.27.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.